IL321560A - Treatment of autoimmune disease - Google Patents

Treatment of autoimmune disease

Info

Publication number
IL321560A
IL321560A IL321560A IL32156025A IL321560A IL 321560 A IL321560 A IL 321560A IL 321560 A IL321560 A IL 321560A IL 32156025 A IL32156025 A IL 32156025A IL 321560 A IL321560 A IL 321560A
Authority
IL
Israel
Prior art keywords
treatment
autoimmune disease
autoimmune
disease
Prior art date
Application number
IL321560A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL321560A publication Critical patent/IL321560A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL321560A 2022-12-19 2025-06-17 Treatment of autoimmune disease IL321560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263476066P 2022-12-19 2022-12-19
PCT/EP2023/086487 WO2024133161A1 (en) 2022-12-19 2023-12-18 Treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
IL321560A true IL321560A (en) 2025-08-01

Family

ID=89474788

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321560A IL321560A (en) 2022-12-19 2025-06-17 Treatment of autoimmune disease

Country Status (14)

Country Link
US (1) US20240199761A1 (en)
EP (1) EP4638507A1 (en)
JP (1) JP2025542239A (en)
KR (1) KR20250124877A (en)
CN (1) CN120476150A (en)
AR (1) AR131398A1 (en)
AU (1) AU2023413552A1 (en)
CL (1) CL2025001822A1 (en)
CO (1) CO2025009742A2 (en)
CR (1) CR20250284A (en)
IL (1) IL321560A (en)
MX (1) MX2025007229A (en)
TW (1) TW202444762A (en)
WO (1) WO2024133161A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators
WO2026136763A1 (en) 2024-12-19 2026-06-25 Bristol-Myers Squibb Company Genetic predictor for il18 driven disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
JPWO2012026309A1 (en) * 2010-08-23 2013-10-28 公立大学法人横浜市立大学 Creation of anti-PAD4 antibody drugs
JP6057299B2 (en) 2011-10-31 2017-01-11 国立大学法人 長崎大学 Preventive or therapeutic agent for viral infection
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
US20150376294A1 (en) 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP6832709B2 (en) 2014-05-16 2021-02-24 メディミューン,エルエルシー Molecules with modified neonatal Fc receptor binding for enhanced therapeutic and diagnostic properties
US11447569B2 (en) 2015-03-06 2022-09-20 Public University Corporation Yokohama City University Anti-PAD4 antibody
WO2016155745A1 (en) 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies
AR124914A1 (en) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp NEW ANTI-PAD4 ANTIBODY

Also Published As

Publication number Publication date
CL2025001822A1 (en) 2025-10-03
JP2025542239A (en) 2025-12-25
CR20250284A (en) 2025-08-29
KR20250124877A (en) 2025-08-20
US20240199761A1 (en) 2024-06-20
CO2025009742A2 (en) 2025-08-08
AR131398A1 (en) 2025-03-12
MX2025007229A (en) 2025-07-01
WO2024133161A1 (en) 2024-06-27
TW202444762A (en) 2024-11-16
CN120476150A (en) 2025-08-12
AU2023413552A1 (en) 2025-07-31
EP4638507A1 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
EP4525871A4 (en) Treatment of depression
IL315503A (en) Methods of treatment
IL320711A (en) Methods of treatment
GB2618915B (en) Treatment of cardiovascular disease
IL299695B1 (en) Treatment of cancer, inflammatory diseases and autoimmune diseases
GB202001353D0 (en) Treatment of skin conditions
GB202109021D0 (en) Treatment for autoimmune diseases
IL327357A (en) Combination treatment of autoimmune disorders
GB202201824D0 (en) Methods of treatment
AU2021343534A9 (en) TREATMENT OF NF-κB-MEDIATED DISEASE
CA3277572A1 (en) Treatment of autoimmune disease
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
IL291626A (en) Treatment of celiac disease
GB202206353D0 (en) Treatment of cervical dystonia
IL307459A (en) Treatment of kidney diseases
GB202404416D0 (en) Treatment of disease
GB202315831D0 (en) Treatment of skin disease
IL326388A (en) Macrocycles for the treatment of autoimmune diseases
GB202102257D0 (en) Treatment of shells
GB202312427D0 (en) Treatment for autoimmune disease
GB202206359D0 (en) Treatment of pain
GB202315695D0 (en) TReatment of cariomyopathy
GB202212506D0 (en) Treatment of covid-19
GB202116795D0 (en) Treatment of visceral pain